On the last check Thursday, OpGen Inc. (OPGN) plunged -4.39% at $2.18 in pre-market trading hours. OpGen’s stock lost -0.87% to close at $2.28 in the last trading session. The price range for the OPGN stock was $2.24 to $2.32. Over the past 100 days, it has traded 6.42 million shares daily on average, which was higher than the OPGN stock volume of 1.34 million on the day. In the last five days, OPGN’s shares fell by -3.39%, while they gained 1.79% in the last month. OPGN stock fell after announcing partial adjournment of the annual meeting.

The OPGN meeting will take place when?

To combat infectious diseases, OpGen combines molecular diagnostics with bioinformatics. As a developer and manufacturer of molecular microbiology solutions, OPGN develops solutions in conjunction with subsidiaries, Curetis GmbH and Ares Genetics GmbH. With OPGN’s solutions, clinicians are provided with more rapid and actionable information regarding potentially life-threatening infections, which can lead to better patient outcomes and a decrease in the spread of infections due to multidrug-resistant microorganisms. Unyvero, Acuitas’ AMR Gene Panel, and Acuitas Lighthouse, are part of OPGN’s product offering, as is the ARES Technology Platform, which uses NGS and AI to predict antibiotic response.

On July 7, 2021, OpGen resumed its partially adjourned 2021 annual stockholders meeting.

• In its Definitive Proxy Statement dated April 26, 2021, OPGN’s annual meeting was delayed solely due to Proposal 2.
• The proxy statement was related to an increase in the number of shares of common stock authorized by OPGN.
• To provide its stockholders with additional time to vote on Proposal 2, OPGN adjourned the Annual Meeting regarding such proposal.
• Proposal 2 will now be discussed at the Annual Meeting at 10:00 am Eastern time on August 5, 2021.
• OPGN’s offices at 9717 Key West Ave, Suite 100, Rockville, MD 20850 will continue to host the Annual Meeting.
• At OPGN’s Annual Meeting, April 5, 2021 will remain the record date for determining who can vote.
• The recent feedback and dialogue with many stockholders, and the number of stockholders who have already voted in favor of this important proposal, are encouraging to OPGN.
• The importance of this proposal for the future success of the OPGN cannot be overstated.
• This proposal is thus unanimously recommended be approved by the OPGN Board.

Why the proposal is important for OPGN?

With its strong cash position of $39.4 million at the end of the second quarter of 2021, these additional authorized shares will provide OpGen (OPGN) with the additional flexibility to seek future funding in order to continue expanding, strategically managing and possibly helping to reduce its long-term debt, and raising additional capital when needed. Management and OPGN’s board of directors have determined that, since this proposal requires an affirmative vote of at least 66.67% of all shares outstanding, alternate options must be explored simultaneously to fund the Company’s growth and development.